Is AIKI or LUNA more profitable?

Luna Innovations' return on equity of 0.00% beat AIkido Pharma's return on equity. Company Net Margins Return on Equity Return on Assets AIkido Pharma N/A -18.21% -16.94% Luna Innovations N/A N/A N/A

Which has better valuation and earnings, AIKI or DKDCA?

Data Knights Acquisition is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AIkido Pharma N/A N/A -$7.17M -$3.88 N/A Data Knights Acquisition N/A N/A $340K -$0.19 N/A

Is AIKI or DKDCA more profitable?

Data Knights Acquisition's return on equity of 0.00% beat AIkido Pharma's return on equity. Company Net Margins Return on Equity Return on Assets AIkido Pharma N/A -18.21% -16.94% Data Knights Acquisition N/A N/A -5.55%

Do analysts recommend TIL or AIKI?

Instil Bio presently has a consensus target price of $66.00, suggesting a potential upside of 806.59%. Given Instil Bio's stronger consensus rating and higher probable upside, analysts plainly believe Instil Bio is more favorable than AIkido Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 AIkido Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, TIL or AIKI?

Instil Bio is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instil Bio N/A N/A -$71.37M -$7.08 N/A AIkido Pharma N/A N/A -$7.17M -$3.88 N/A

Is TIL or AIKI more profitable?

AIkido Pharma's return on equity of -18.21% beat Instil Bio's return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -39.76% -22.38% AIkido Pharma N/A -18.21% -16.94%

Do analysts recommend ATYR or AIKI?

aTyr Pharma currently has a consensus price target of $17.00, suggesting a potential upside of 3,286.45%. Given aTyr Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe aTyr Pharma is more favorable than AIkido Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25 AIkido Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ATYR or AIKI more profitable?

AIkido Pharma's return on equity of -18.21% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets aTyr Pharma N/A -100.14% -73.55% AIkido Pharma N/A -18.21% -16.94%

Do analysts recommend AIKI or SRTS?

Sensus Healthcare has a consensus target price of $6.88, suggesting a potential upside of 130.70%. Given Sensus Healthcare's stronger consensus rating and higher probable upside, analysts clearly believe Sensus Healthcare is more favorable than AIkido Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AIkido Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Sensus Healthcare 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

AIkido Pharma (AIKI) Competitors

$2.47 -0.09 (-3.52%)

As of 08/5/2026

Compare

AIKI vs. LUNA, DKDCA, TIL, ATYR, and SRTS

Should you buy AIkido Pharma stock or one of its competitors? MarketBeat compares AIkido Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AIkido Pharma include Luna Innovations (LUNA), Data Knights Acquisition (DKDCA), Instil Bio (TIL), aTyr Pharma (ATYR), and Sensus Healthcare (SRTS).

How does AIkido Pharma compare to Luna Innovations?

AIkido Pharma (NASDAQ:AIKI) and Luna Innovations (NASDAQ:LUNA) are related small-cap companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Luna Innovations has higher revenue and earnings than AIkido Pharma. AIkido Pharma is trading at a lower price-to-earnings ratio than Luna Innovations, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AIkido Pharma	N/A	N/A	-$7.17M	-$3.88	N/A
Luna Innovations	$116.61M	0.37	$9.28M	$0.06	21.00

In the previous week, Luna Innovations had 1 more articles in the media than AIkido Pharma. MarketBeat recorded 1 mentions for Luna Innovations and 0 mentions for AIkido Pharma. Luna Innovations' average media sentiment score of 0.67 beat AIkido Pharma's score of 0.00 indicating that Luna Innovations is being referred to more favorably in the news media.

Company	Overall Sentiment
AIkido Pharma	Neutral
Luna Innovations	Positive

AIkido Pharma has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Luna Innovations has a beta of 1.89, suggesting that its share price is 89% more volatile than the broader market.

10.9% of AIkido Pharma shares are owned by institutional investors. Comparatively, 87.5% of Luna Innovations shares are owned by institutional investors. 8.6% of AIkido Pharma shares are owned by company insiders. Comparatively, 7.6% of Luna Innovations shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Luna Innovations' return on equity of 0.00% beat AIkido Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AIkido Pharma	N/A	-18.21%	-16.94%
Luna Innovations	N/A	N/A	N/A

Summary

Luna Innovations beats AIkido Pharma on 10 of the 11 factors compared between the two stocks.

How does AIkido Pharma compare to Data Knights Acquisition?

AIkido Pharma (NASDAQ:AIKI) and Data Knights Acquisition (NASDAQ:DKDCA) are related small-cap companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

10.9% of AIkido Pharma shares are held by institutional investors. Comparatively, 35.3% of Data Knights Acquisition shares are held by institutional investors. 8.6% of AIkido Pharma shares are held by insiders. Comparatively, 45.7% of Data Knights Acquisition shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Data Knights Acquisition's return on equity of 0.00% beat AIkido Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AIkido Pharma	N/A	-18.21%	-16.94%
Data Knights Acquisition	N/A	N/A	-5.55%

AIkido Pharma has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Data Knights Acquisition has a beta of 0.18, indicating that its stock price is 82% less volatile than the broader market.

Data Knights Acquisition is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AIkido Pharma	N/A	N/A	-$7.17M	-$3.88	N/A
Data Knights Acquisition	N/A	N/A	$340K	-$0.19	N/A

In the previous week, AIkido Pharma's average media sentiment score of 0.00 equaled Data Knights Acquisition'saverage media sentiment score.

Company	Overall Sentiment
AIkido Pharma	Neutral
Data Knights Acquisition	Neutral

Summary

Data Knights Acquisition beats AIkido Pharma on 6 of the 8 factors compared between the two stocks.

How does AIkido Pharma compare to Instil Bio?

Instil Bio (NASDAQ:TIL) and AIkido Pharma (NASDAQ:AIKI) are related small-cap companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

In the previous week, Instil Bio's average media sentiment score of 0.00 equaled AIkido Pharma'saverage media sentiment score.

Company	Overall Sentiment
Instil Bio	Neutral
AIkido Pharma	Neutral

Instil Bio presently has a consensus target price of $66.00, suggesting a potential upside of 806.59%. Given Instil Bio's stronger consensus rating and higher probable upside, analysts plainly believe Instil Bio is more favorable than AIkido Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
AIkido Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

AIkido Pharma's return on equity of -18.21% beat Instil Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
AIkido Pharma	N/A	-18.21%	-16.94%

Instil Bio has a beta of 1.94, suggesting that its share price is 94% more volatile than the broader market. Comparatively, AIkido Pharma has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

60.6% of Instil Bio shares are held by institutional investors. Comparatively, 10.9% of AIkido Pharma shares are held by institutional investors. 47.0% of Instil Bio shares are held by company insiders. Comparatively, 8.6% of AIkido Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Instil Bio is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
AIkido Pharma	N/A	N/A	-$7.17M	-$3.88	N/A

Summary

Instil Bio and AIkido Pharma tied by winning 5 of the 10 factors compared between the two stocks.

How does AIkido Pharma compare to aTyr Pharma?

aTyr Pharma (NASDAQ:ATYR) and AIkido Pharma (NASDAQ:AIKI) are related small-cap companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

AIkido Pharma has lower revenue, but higher earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	259.06	-$74.12M	-$0.73	N/A
AIkido Pharma	N/A	N/A	-$7.17M	-$3.88	N/A

In the previous week, aTyr Pharma's average media sentiment score of 0.00 equaled AIkido Pharma'saverage media sentiment score.

Company	Overall Sentiment
aTyr Pharma	Neutral
AIkido Pharma	Neutral

AIkido Pharma's return on equity of -18.21% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-100.14%	-73.55%
AIkido Pharma	N/A	-18.21%	-16.94%

61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 10.9% of AIkido Pharma shares are held by institutional investors. 5.8% of aTyr Pharma shares are held by insiders. Comparatively, 8.6% of AIkido Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

aTyr Pharma currently has a consensus price target of $17.00, suggesting a potential upside of 3,286.45%. Given aTyr Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe aTyr Pharma is more favorable than AIkido Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
AIkido Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

aTyr Pharma has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, AIkido Pharma has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

Summary

aTyr Pharma beats AIkido Pharma on 7 of the 13 factors compared between the two stocks.

How does AIkido Pharma compare to Sensus Healthcare?

AIkido Pharma (NASDAQ:AIKI) and Sensus Healthcare (NASDAQ:SRTS) are related small-cap companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

AIkido Pharma has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Sensus Healthcare has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

AIkido Pharma has a net margin of 0.00% compared to Sensus Healthcare's net margin of -34.50%. Sensus Healthcare's return on equity of -15.79% beat AIkido Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AIkido Pharma	N/A	-18.21%	-16.94%
Sensus Healthcare	-34.50%	-15.79%	-14.02%

AIkido Pharma has higher earnings, but lower revenue than Sensus Healthcare. Sensus Healthcare is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AIkido Pharma	N/A	N/A	-$7.17M	-$3.88	N/A
Sensus Healthcare	$27.48M	1.78	-$7.72M	-$0.47	N/A

Sensus Healthcare has a consensus target price of $6.88, suggesting a potential upside of 130.70%. Given Sensus Healthcare's stronger consensus rating and higher probable upside, analysts clearly believe Sensus Healthcare is more favorable than AIkido Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AIkido Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sensus Healthcare	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

10.9% of AIkido Pharma shares are held by institutional investors. Comparatively, 25.3% of Sensus Healthcare shares are held by institutional investors. 8.6% of AIkido Pharma shares are held by insiders. Comparatively, 10.2% of Sensus Healthcare shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, AIkido Pharma's average media sentiment score of 0.00 equaled Sensus Healthcare'saverage media sentiment score.

Company	Overall Sentiment
AIkido Pharma	Neutral
Sensus Healthcare	Neutral

Summary

Sensus Healthcare beats AIkido Pharma on 10 of the 13 factors compared between the two stocks.

Get AIkido Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIKI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIKI vs. The Competition

Export

Metric	AIkido Pharma	Capital Markets Industry	Finance Sector	NASDAQ Exchange
Market Cap	$13.55M	$5.60B	$14.07B	$12.87B
Dividend Yield	N/A	7.46%	5.92%	9.95%
P/E Ratio	-0.64	38.23	29.34	25.32
Price / Sales	N/A	1,273.21	514.25	83.09
Price / Cash	N/A	48.28	39.25	50.37
Price / Book	0.13	3.75	3.72	6.13
Net Income	-$7.17M	$417.17M	$1.31B	$342.95M
7 Day Performance	10.76%	1.28%	1.13%	3.03%
1 Month Performance	-15.99%	-0.45%	0.48%	-3.04%
1 Year Performance	-54.51%	6.60%	13.19%	20.65%

AIkido Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIKI AIkido Pharma	N/A	$2.47 -3.5%	N/A	-43.1%	$13.55M	N/A	N/A	4
LUNA Luna Innovations	N/A	$1.24 -0.8%	N/A	+32.6%	$42.11M	$116.61M	20.67	390
DKDCA Data Knights Acquisition	N/A	$0.64 -9.4%	N/A	+47.8%	$3.32M	N/A	N/A	2	Gap Up High Trading Volume
TIL Instil Bio	1.5178 of 5 stars	$7.15 -1.0%	$66.00 +823.7%	-73.1%	$48.83M	N/A	N/A	410	Positive News Upcoming Earnings
ATYR aTyr Pharma	3.1617 of 5 stars	$0.49 +1.2%	$17.00 +3,376.5%	-89.9%	$47.95M	$190K	N/A	53

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIKI) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AIkido Pharma (AIKI) Competitors

AIKI vs. LUNA, DKDCA, TIL, ATYR, and SRTS

How does AIkido Pharma compare to Luna Innovations?

Summary

How does AIkido Pharma compare to Data Knights Acquisition?

Summary

How does AIkido Pharma compare to Instil Bio?

Summary

How does AIkido Pharma compare to aTyr Pharma?

Summary

How does AIkido Pharma compare to Sensus Healthcare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIKI vs. The Competition

AIkido Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AIkido Pharma (AIKI) Competitors

AIKI vs. LUNA, DKDCA, TIL, ATYR, and SRTS

How does AIkido Pharma compare to Luna Innovations?

Which has preferable valuation and earnings, AIKI or LUNA?

Does the media prefer AIKI or LUNA?

Which has more risk & volatility, AIKI or LUNA?

Do insiders & institutionals believe in AIKI or LUNA?

Is AIKI or LUNA more profitable?

Summary

How does AIkido Pharma compare to Data Knights Acquisition?

Do institutionals & insiders have more ownership in AIKI or DKDCA?

Is AIKI or DKDCA more profitable?

Which has more volatility and risk, AIKI or DKDCA?

Which has better valuation and earnings, AIKI or DKDCA?

Does the media favor AIKI or DKDCA?

Summary

How does AIkido Pharma compare to Instil Bio?

Does the media prefer TIL or AIKI?

Do analysts recommend TIL or AIKI?

Is TIL or AIKI more profitable?

Which has more risk & volatility, TIL or AIKI?

Do insiders and institutionals hold more shares of TIL or AIKI?

Which has stronger earnings and valuation, TIL or AIKI?

Summary

How does AIkido Pharma compare to aTyr Pharma?

Which has better valuation and earnings, ATYR or AIKI?

Does the media favor ATYR or AIKI?

Is ATYR or AIKI more profitable?

Do insiders & institutionals hold more shares of ATYR or AIKI?

Do analysts recommend ATYR or AIKI?

Which has more volatility & risk, ATYR or AIKI?

Summary

How does AIkido Pharma compare to Sensus Healthcare?

Which has more risk and volatility, AIKI or SRTS?

Is AIKI or SRTS more profitable?

Which has stronger valuation & earnings, AIKI or SRTS?

Do analysts recommend AIKI or SRTS?

Do institutionals and insiders hold more shares of AIKI or SRTS?

Does the media refer more to AIKI or SRTS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIKI vs. The Competition

AIkido Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools